Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186930 | 1.00 | LGALS8 (0.56) | LGALS8NPC1RAB9ATYRMEN1 | |
| SCHEMBL23121475 | 0.90 | LGALS8 (0.50) | LGALS8NPC1RAB9ATYRMEN1 | |
| SCHEMBL7998397 | 0.90 | MEN1 (0.54) | LGALS8MEN1TP53CYP3A4KMT2A | |
| SCHEMBL9181428 | 0.85 | ALDH1A1 (0.47) | TYR | |
| SCHEMBL9181422 | 0.85 | ALDH1A1 (0.47) | TYR | |
| SCHEMBL13755879 | 0.84 | CYP3A4 (0.54) | MEN1TP53CYP3A4KMT2ACYP2C9 | |
| SCHEMBL30361411 | 0.82 | TYR (0.65) | TYR | |
| SCHEMBL4189072 | 0.82 | CYP3A4 (0.49) | LGALS8MEN1TP53CYP3A4KMT2A | |
| SCHEMBL13755884 | 0.81 | CYP3A4 (0.63) | MEN1TP53CYP3A4KMT2ACYP2C9 | |
| SCHEMBL12870233 | 0.81 | CYP3A4 (0.63) | MEN1TP53CYP3A4KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215710-A1 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215710-A1 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | TLR4, TLR1, TLR2 | LGALS8 134/4885NPC1 2638/4885RAB9A 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.